Latest update on the use of recombinant growth factors for periodontal regeneration: existing evidence and clinical applications
Therapeutic Advances in Chronic Disease,
Год журнала:
2024,
Номер
15
Опубликована: Янв. 1, 2024
Growth
factors
were
introduced
to
increase
predictability
in
periodontal
regeneration
and
have
since
been
widely
applied
dentistry.
This
narrative
review
article
highlights
histological
latest
findings
of
recombinant
human
platelet-derived
growth
factor-BB
(rhPDGF-BB)
fibroblast
factor-2
(rhFGF-2)
for
regeneration.
rhPDGF-BB
enhances
the
proliferation
chemotaxis
ligament
alveolar
bone
cells.
The
optimal
dose
rhPDGF-BB,
combination
with
beta-tricalcium
phosphate,
is
0.3
mg/ml.
It
approved
United
States,
Canada,
Taiwan
use
treatment
gingival
recession.
rhFGF-2
promotes
wound
healing
through
mitogenic
angiogenic
effects
on
mesenchymal
cells
ligament.
Japan
at
an
0.3%
intrabony
defects.
Both
show
evidence
new
bone,
cementum,
Clinical
studies
demonstrate
improved
clinical
attachment
levels
defect
resolution
treating
furcation
Presented
cases
consensus
reports
may
serve
as
a
reference
clinicians.
are
safe
effective
biologics
that
can
be
improve
outcomes
Язык: Английский
A BiO‐Optimizing Site Targeted (BOOST) Approach to Periodontal Regeneration Through Local Doxycycline Prior to Surgery: A Randomized Clinical Trial
Journal of Periodontal Research,
Год журнала:
2025,
Номер
unknown
Опубликована: Янв. 27, 2025
ABSTRACT
Aim
To
test
a
BiO‐Optimizing
Site
Targeted
(BOOST)
approach
to
periodontal
regeneration
by
the
adjunctive
use
of
locally
delivered
doxycycline
(DOX)
2
weeks
prior
minimally
invasive
surgery
in
terms
clinical
and
radiographic
outcomes
at
1
year.
Methods
For
this
randomized
trial,
stage
III/IV
periodontitis
patients
presenting
sites
with
intrabony
defects
bleeding
on
probing
(BoP+)
after
steps
1–2
treatment
were
included.
Sites
treated
via
subgingival
instrumentation
or
without
BOOST
local
DOX.
After
weeks,
accessed
surgical
technique
xenograft
amelogenins.
Primary
(clinical
attachment
level
[CAL]
gain)
secondary
(probing
pocket
depth
[PPD]
reduction,
composite
outcomes,
bone
defect
fill)
assessed
12
months.
Results
Sixty
completed
study
(30
each
group).
led
lower
preoperative
BoP
(
p
<
0.001)
better
wound
healing
=
0.027).
Both
groups
showed
improvements
year,
significant
differences
mean
CAL
gain
(4.1
±
1.9
vs.
3.2
2.0
mm;
0.019)
PPD
reduction
(4.4
1.8
3.6
0.040)
favoring
group.
group
also
achieved
higher
outcome
measure
(PPD
≤
4
mm
≥
3;
83.3%
46.7%;
0.006),
closure
3
BoP−;
60.0%;
0.045),
fill
(3.5
1.2
2.7
1.3
compared
control
Conclusion
A
before
enhanced
inflammatory
post‐operative
early
healing,
yielding
improved
Trial
Registration
ClinicalTrials.gov
identifier:
NCT05878353
Язык: Английский
Factors influencing pocket closure in surgically-treated intraosseous defects. A retrospective analysis
Clinical Oral Investigations,
Год журнала:
2025,
Номер
29(6)
Опубликована: Май 28, 2025
Язык: Английский
30 years of enamel matrix derivative: Mimicking tooth development as a clinical concept
Periodontology 2000,
Год журнала:
2025,
Номер
unknown
Опубликована: Июнь 3, 2025
Abstract
The
use
of
growth
factors
(GFs)
has
become
a
cornerstone
modern
regenerative
periodontology.
While
the
extent
to
which
GFs
enhance
tissue
regeneration
compared
other
biomaterials
was
initially
uncertain,
it
is
now
well
established
that
play
critical
role
in
various
types.
In
context
periodontal
regeneration,
enamel
matrix
derivative
(EMD/Emdogain)
been
key
biomaterial
for
over
30
years.
Pioneering
work
by
Lars
Hammarström
mid‐1990s
led
wealth
publications
on
clinical
concept
mimicking
tooth
development
promote
regeneration.
This
approach
shown
induce
formation
new
cementum,
with
functionally
oriented
ligament
fibers
and
alveolar
bone.
review
begins
an
overview
biological
basis
EMD,
highlighting
its
as
protein
(primarily
amelogenins)
factor
complex
initiates
mimics
development.
Subsequently,
histological
evidence
from
animal
human
studies
using
EMD
presented,
alongside
discussion
ongoing
research
avenues.
Clinical
outcomes
are
then
narratively
reviewed,
focusing
safety,
early
wound
healing
properties,
applications
scenarios,
including
non‐surgical
therapy,
intra‐bony
furcation
defects,
adjunct
soft‐tissue
grafting.
gained
tremendous
past
years
GF
capable
enhancing
both
hard
soft
therapy.
Язык: Английский
Impact of Inflammatory Markers and Senescence-Associated Secretory Phenotype in the Gingival Crevicular Fluid on the Outcomes of Periodontal Regeneration
International Journal of Molecular Sciences,
Год журнала:
2024,
Номер
25(12), С. 6687 - 6687
Опубликована: Июнь 18, 2024
The
aim
of
this
study
was
to
test
the
molecular
expression
profile
(senescence-associated
secretory
phenotype;
SASP)
in
gingival
crevicular
fluid
(GCF)
prior
surgery
relation
distribution
clinical
success
periodontal
regeneration.
Forty
consecutive
patients
presenting
sites
with
residual
probing
pocket
depth
(PPD)
≥
6
mm
and
intrabony
defects
3
were
treated
through
a
minimally
invasive
surgical
technique.
Pre-operatively,
GCF
sampled
for
inflammatory
biomarker
analysis
related
SASP
[interleukin
(IL)-1β,
IL-6,
IL-12;
matrix-metalloproteinases
(MMP)-8
-9].
Better
or
worse
responders
classified
depending
on
achievement
composite
outcome
measure
at
1-year
[COM;
PPD
≤
4
attachment
gain
(CAL)
mm].
Correlation
analyses
logistic
regression
models
performed.
Periodontal
regeneration
led
significant
improvements
mean
radiographic
parameters.
Teeth
achieving
COM
presented
significantly
lower
amounts
factors
compared
non-successful
teeth.
Higher
CAL
gain,
reduction,
bone
fill
negatively
correlated
IL-1β
MMP-8
-9
(p
<
0.001),
while
IL-12
showed
direct
relationship
=
0.005)
reduction
0.038).
Sites
expressing
higher
before
achieved
outcomes.
Язык: Английский
Saving a hopeless tooth with a four‐wall bone defect: A case report
Clinical Advances in Periodontics,
Год журнала:
2024,
Номер
unknown
Опубликована: Дек. 23, 2024
Recombinant
human
fibroblast
growth
factor-2
(rhFGF-2)
has
been
shown
to
effectively
promote
the
formation
of
new
periodontal
tissues,
and
its
efficacy
demonstrated
in
clinical
settings.
Moreover,
radiographic
outcomes
treatment
infrabony
defects
can
be
improved
by
using
rhFGF-2
combination
with
a
bone
substitute.
Here,
we
present
case
four-wall
defect
tooth
treated
regenerative
therapy
beta-tricalcium
phosphate
(β-TCP).
Язык: Английский